{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T18:25:17Z","timestamp":1776363917620,"version":"3.51.2"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NIH","award":["K08AR070285-03"],"award-info":[{"award-number":["K08AR070285-03"]}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.trsl.2019.02.010","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T12:33:27Z","timestamp":1550925207000},"page":"77-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis"],"prefix":"10.1016","volume":"209","author":[{"given":"Benjamin","family":"Korman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2019.02.010_bib0001","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.trsl.2019.02.010_bib0002","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/1753465817713680","article-title":"Evaluation and management approaches for scleroderma lung disease","volume":"11","author":"Schoenfeld","year":"2017","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0003","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.ajpath.2012.02.004","article-title":"Recent developments in myofibroblast biology: paradigms for connective tissue remodeling","volume":"180","author":"Hinz","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0004","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/BOR.0000000000000217","article-title":"Origin of fibrosing cells in systemic sclerosis","volume":"27","author":"Ebmeier","year":"2015","journal-title":"Curr Opin Rheumatol"},{"issue":"6417","key":"10.1016\/j.trsl.2019.02.010_bib0005","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar2971","article-title":"Myofibroblast proliferation and heterogeneity are supported by macrophages during skin repair","volume":"362","author":"Shook","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.trsl.2019.02.010_bib0006","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1084\/jem.20160247","article-title":"Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: possible roles in scleroderma","volume":"214","author":"Takahashi","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.trsl.2019.02.010_bib0007","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/annrheumdis-2016-210229","article-title":"Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis","volume":"76","author":"Manetti","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0008","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/art.39421","article-title":"Endothelial cells expressing endothelial and mesenchymal cell gene products in lung tissue from patients with systemic sclerosis-associated interstitial lung disease","volume":"68","author":"Mendoza","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0009","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/art.38572","article-title":"Caveolin-1 deficiency may predispose African Americans to systemic sclerosis-related interstitial lung disease","volume":"66","author":"Reese","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0010","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/art.38990","article-title":"Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors","volume":"67","author":"Marangoni","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0011","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature12783","article-title":"Distinct fibroblast lineages determine dermal architecture in skin development and repair","volume":"504","author":"Driskell","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2019.02.010_bib0012","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaa2151","article-title":"Skin fibrosis. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential","author":"Rinkevich","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.trsl.2019.02.010_bib0013","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jid.2017.10.012","article-title":"A fibroblast is not a fibroblast is not a fibroblast","volume":"138","author":"Hu","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0014","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jid.2018.01.016","article-title":"Spatial and single-cell transcriptional profiling identifies functionally distinct human dermal fibroblast subpopulations","volume":"138","author":"Philippeos","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0015","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jid.2017.09.045","article-title":"SFRP2\/DPP4 and FMO1\/LSP1 define major fibroblast populations in human skin","volume":"138","author":"Tabib","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0016","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41467-018-02892-y","article-title":"Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis","volume":"9","author":"Mizoguchi","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2019.02.010_bib0017","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/BOR.0000000000000543","article-title":"Insights into myofibroblasts and their activation in scleroderma: opportunities for therapy","volume":"30","author":"Gyftaki-Venieri","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0018","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/annrheumdis-2014-205303","article-title":"Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies","volume":"74","author":"Altorok","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0019","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/annrheumdis-2018-213022","article-title":"Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts","volume":"77","author":"He","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2017-211501","article-title":"The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis","volume":"77","author":"Bergmann","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0021","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/annrheumdis-2012-203194","article-title":"The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis","volume":"73","author":"Dees","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0022","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/jid.2012.479","article-title":"p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-beta: epigenetic feed-forward amplification of fibrosis","volume":"133","author":"Ghosh","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0023","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/art.39061","article-title":"The histone deacetylase sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor beta signaling","volume":"67","author":"Wei","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0024","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1038\/ncomms6797","article-title":"Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis","volume":"5","author":"Noda","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2019.02.010_bib0025","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/art.38948","article-title":"Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice","volume":"67","author":"Taniguchi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0026","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jid.2017.04.035","article-title":"Systemic sclerosis dermal fibroblasts suppress Th1 cytokine production via galectin-9 overproduction due to Fli1 deficiency","volume":"137","author":"Saigusa","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0027","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/BOR.0000000000000218","article-title":"Update on macrophages and innate immunity in scleroderma","volume":"27","author":"Chia","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0028","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2016-210189","article-title":"Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages","volume":"76","author":"Maier","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0029","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/art.38275","article-title":"Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis","volume":"66","author":"Wu","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0030","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","article-title":"Association of Interferon- and transforming growth factor beta-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis","volume":"66","author":"Christmann","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0031","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1172\/JCI99088","article-title":"PAI1 mediates fibroblast-mast cell interactions in skin fibrosis","volume":"128","author":"Pincha","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2019.02.010_bib0032","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam8458","article-title":"Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8","volume":"10","author":"Ah Kioon","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2019.02.010_bib0033","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1172\/JCI85740","article-title":"Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis","volume":"126","author":"Chia","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2019.02.010_bib0034","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature12614","article-title":"Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma","volume":"503","author":"Gerber","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2019.02.010_bib0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2019.02.010_bib0036","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98850","article-title":"TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung","volume":"3","author":"Bhattacharyya","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.trsl.2019.02.010_bib0037","doi-asserted-by":"crossref","first-page":"11703","DOI":"10.1038\/ncomms11703","article-title":"Tenascin-C drives persistence of organ fibrosis","volume":"7","author":"Bhattacharyya","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2019.02.010_bib0038","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008264","article-title":"FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling","volume":"6","author":"Bhattacharyya","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2019.02.010_bib0039","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/art.39655","article-title":"Toll-like receptor 9 signaling is augmented in systemic sclerosis and elicits transforming growth factor beta-dependent fibroblast activation","volume":"68","author":"Fang","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0040","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1002\/art.30568","article-title":"The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis","volume":"63","author":"Artlett","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2019.02.010_bib0041","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3389\/fimmu.2018.01702","article-title":"Innate immunity in systemic sclerosis fibrosis: recent advances","volume":"9","author":"Laurent","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0042","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0043","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1002\/art.39797","article-title":"An autotaxin\/lysophosphatidic acid\/interleukin-6 amplification loop drives scleroderma fibrosis","volume":"68","author":"Castelino","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0044","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.autrev.2018.01.012","article-title":"Systemic lupus erythematosus and systemic sclerosis: all roads lead to platelets","volume":"17","author":"Scherlinger","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.trsl.2019.02.010_bib0045","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0046","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1136\/annrheumdis-2011-200901","article-title":"IRF5 polymorphism predicts prognosis in patients with systemic sclerosis","volume":"71","author":"Sharif","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0047","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0048","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/art.40016","article-title":"Scleroderma peripheral B lymphocytes secrete interleukin-6 and transforming growth factor beta and activate fibroblasts","volume":"69","author":"Dumoitier","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0049","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/BOR.0000000000000325","article-title":"Progress in understanding the diagnostic and pathogenic role of autoantibodies associated with systemic sclerosis","volume":"28","author":"Choi","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0050","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/art.39437","article-title":"Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis","volume":"68","author":"Mavropoulos","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0051","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aas9944","article-title":"BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance","author":"Matsushita","year":"2018","journal-title":"Sci Adv"},{"key":"10.1016\/j.trsl.2019.02.010_bib0052","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jid.2016.11.037","article-title":"Skin-resident effector memory CD8(+)CD28(-) T cells exhibit a profibrotic phenotype in patients with systemic sclerosis","volume":"137","author":"Li","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0053","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/art.37706","article-title":"Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis","volume":"65","author":"Fuschiotti","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2019.02.010_bib0054","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1002\/art.39817","article-title":"Platelets induce thymic stromal lymphopoietin production by endothelial cells: contribution to fibrosis in human systemic sclerosis","volume":"68","author":"Truchetet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0055","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ni.3489","article-title":"Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis","volume":"17","author":"Klose","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0056","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.4049\/jimmunol.1501491","article-title":"CD4+ group 1 innate lymphoid cells (ILC) form a functionally distinct ILC subset that is increased in systemic sclerosis","volume":"196","author":"Roan","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0057","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao3089","article-title":"Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis","volume":"10","author":"Maugeri","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2019.02.010_bib0058","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.37705","article-title":"Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)\/transforming growth factor beta-dependent mesenchymal-to-mesenchymal transition","volume":"65","author":"Serrati","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2019.02.010_bib0059","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1136\/annrheumdis-2013-203535","article-title":"Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis","volume":"73","author":"Maurer","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0060","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13075-017-1356-3","article-title":"Anti-connective tissue growth factor (CTGF\/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis","volume":"19","author":"Makino","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.trsl.2019.02.010_bib0061","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13075-016-1011-4","article-title":"Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice","volume":"18","author":"Akashi","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.trsl.2019.02.010_bib0062","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1165\/rcmb.2011-0446OC","article-title":"Adenoviral gene transfer of endothelin-1 in the lung induces pulmonary fibrosis through the activation of focal adhesion kinase","volume":"47","author":"Lagares","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0063","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/art.30312","article-title":"Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma","volume":"63","author":"Wei","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2019.02.010_bib0064","doi-asserted-by":"crossref","first-page":"e13778","DOI":"10.1371\/journal.pone.0013778","article-title":"PPARgamma downregulation by TGFss in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis","volume":"5","author":"Wei","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2019.02.010_bib0065","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/annrheumdis-2012-202716","article-title":"A synthetic PPAR-gamma agonist triterpenoid ameliorates experimental fibrosis: PPAR-gamma-independent suppression of fibrotic responses","volume":"73","author":"Wei","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0066","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","article-title":"Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis","volume":"75","author":"Ruzehaji","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0067","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13075-018-1630-z","article-title":"Adipocyte-specific repression of PPAR-gamma by NCoR contributes to scleroderma skin fibrosis","volume":"20","author":"Korman","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.trsl.2019.02.010_bib0068","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1038\/s41598-017-04162-1","article-title":"Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target","volume":"7","author":"Marangoni","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2019.02.010_bib0069","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13073-017-0417-1","article-title":"A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis","volume":"9","author":"Taroni","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.trsl.2019.02.010_bib0070","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jid.2016.12.007","article-title":"A functional genomic meta-analysis of clinical trials in systemic sclerosis: toward precision medicine and combination therapy","volume":"137","author":"Taroni","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0071","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/rheumatology\/kex280","article-title":"Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta","volume":"56","author":"McCoy","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.trsl.2019.02.010_bib0072","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","article-title":"Transforming growth factor beta\u2013at the centre of systemic sclerosis","volume":"10","author":"Lafyatis","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0073","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fphar.2014.00123","article-title":"Fibroblasts in fibrosis: novel roles and mediators","volume":"5","author":"Kendall","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0074","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fmed.2015.00059","article-title":"Signaling in fibrosis: TGF-beta, WNT, and YAP\/TAZ converge","volume":"2","author":"Piersma","year":"2015","journal-title":"Front Med"},{"key":"10.1016\/j.trsl.2019.02.010_bib0075","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s41467-017-01168-1","article-title":"PTP4A1 promotes TGFbeta signaling and fibrosis in systemic sclerosis","volume":"8","author":"Sacchetti","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2019.02.010_bib0076","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2019.02.010_bib0077","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/art.34424","article-title":"Wnt\/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells","volume":"64","author":"Wei","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2019.02.010_bib0078","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2012-202544","article-title":"Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis","volume":"72","author":"Beyer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0079","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.jid.2017.06.032","article-title":"Inhibition of beta-catenin signaling in the skin rescues cutaneous adipogenesis in systemic sclerosis: a randomized, double-blind, placebo-controlled trial of C-82","volume":"137","author":"Lafyatis","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0080","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1002\/art.34444","article-title":"Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis","volume":"64","author":"Horn","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2019.02.010_bib0081","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/art.30254","article-title":"Inhibition of notch signaling prevents experimental fibrosis and induces regression of established fibrosis","volume":"63","author":"Dees","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2019.02.010_bib0082","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jid.2017.08.024","article-title":"Therapeutic targeting of TAZ and YAP by dimethyl fumarate in systemic sclerosis fibrosis","volume":"138","author":"Toyama","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0083","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/annrheumdis-2013-204221","article-title":"Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability","volume":"73","author":"Distler","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0084","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1073\/pnas.1621375114","article-title":"Unifying mechanism for different fibrotic diseases","volume":"114","author":"Wernig","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.trsl.2019.02.010_bib0085","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/annrheumdis-2011-200940","article-title":"Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis","volume":"71","author":"Maurer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0086","doi-asserted-by":"crossref","first-page":"E3901","DOI":"10.1073\/pnas.1523512113","article-title":"OX40L blockade protects against inflammation-driven fibrosis","volume":"113","author":"Elhai","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.trsl.2019.02.010_bib0087","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","article-title":"Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2019.02.010_bib0088","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.40569","article-title":"JAK\/STAT blockade alters synovial bioenergetics, mitochondrial function, and proinflammatory mediators in rheumatoid arthritis","volume":"70","author":"McGarry","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0089","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.30171","article-title":"Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis","volume":"63","author":"Avouac","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2019.02.010_bib0090","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1002\/art.24958","article-title":"Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1\/Th2 cytokines","volume":"60","author":"Gourh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2019.02.010_bib0091","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.jid.2017.03.032","article-title":"Blockade of PDGF receptors by crenolanib has therapeutic effect in patient fibroblasts and in preclinical models of systemic sclerosis","volume":"137","author":"Makino","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0092","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/BOR.0000000000000219","article-title":"Systemic sclerosis-associated fibrosis: an accelerated aging phenotype","volume":"27","author":"Luckhardt","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0093","doi-asserted-by":"crossref","first-page":"69321","DOI":"10.18632\/oncotarget.12504","article-title":"SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis","volume":"7","author":"Akamata","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2019.02.010_bib0094","doi-asserted-by":"crossref","first-page":"L945","DOI":"10.1152\/ajplung.00473.2016","article-title":"Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts","volume":"312","author":"Wyman","year":"2017","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0095","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/annrheumdis-2014-205740","article-title":"Sirt1 regulates canonical TGF-beta signalling to control fibroblast activation and tissue fibrosis","volume":"75","author":"Zerr","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0096","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fmed.2018.00010","article-title":"Idiopathic pulmonary fibrosis: aging, mitochondrial dysfunction, and cellular bioenergetics","volume":"5","author":"Zank","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.trsl.2019.02.010_bib0097","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2017-212265","article-title":"Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0098","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/art.39575","article-title":"Netrin-1 regulates fibrocyte accumulation in the decellularized fibrotic sclerodermatous lung microenvironment and in bleomycin-induced pulmonary fibrosis","volume":"68","author":"Sun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0099","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/S0003-4967(24)43384-0","article-title":"Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls","volume":"60","author":"Young-Min","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2019.02.010_bib0100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1242\/dmm.012062","article-title":"Diverse functions of matrix metalloproteinases during fibrosis","volume":"7","author":"Giannandrea","year":"2014","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.trsl.2019.02.010_bib0101","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.201411-2044ED","article-title":"Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions","volume":"191","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.trsl.2019.02.010_bib0102","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0103","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2019.02.010_bib0104","first-page":"S97","article-title":"Clinical trial design in scleroderma: where are we and where do we go next","volume":"30","author":"Chung","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American College of Rheumatology Provisional Composite Response Index for clinical trials in early diffuse cutaneous systemic sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0106","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/BOR.0000000000000237","article-title":"Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data","volume":"28","author":"Martyanov","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0107","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.matbio.2018.01.025","article-title":"New developments on skin fibrosis\u2014essential signals emanating from the extracellular matrix for the control of myofibroblasts","volume":"68\u201369","author":"Schulz","year":"2018","journal-title":"Matrix Biol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0108","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00281-015-0551-z","article-title":"Systemic sclerosis and localized scleroderma\u2014current concepts and novel targets for therapy","volume":"38","author":"Distler","year":"2016","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0109","doi-asserted-by":"crossref","DOI":"10.5041\/RMMJ.10257","article-title":"Targeted therapy in systemic sclerosis","volume":"7","author":"Baron","year":"2016","journal-title":"Rambam Maimonides Med J"},{"key":"10.1016\/j.trsl.2019.02.010_bib0110","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3389\/fimmu.2018.02452","article-title":"Unraveling SSc pathophysiology; the myofibroblast","volume":"9","author":"van Caam","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0111","doi-asserted-by":"crossref","first-page":"e89073","DOI":"10.1172\/jci.insight.89073","article-title":"Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity","volume":"1","author":"Lofgren","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.trsl.2019.02.010_bib0112","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/jid.2013.130","article-title":"Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis","volume":"133","author":"Hinchcliff","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0113","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/BOR.0000000000000110","article-title":"Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy","volume":"26","author":"Castelino","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0114","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3899\/jrheum.150996","article-title":"Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis","volume":"43","author":"Cipriani","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.trsl.2019.02.010_bib0115","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/art.37859","article-title":"Thymic stromal lymphopoietin is up-regulated in the skin of patients with systemic sclerosis and induces profibrotic genes and intracellular signaling that overlap with those induced by interleukin-13 and transforming growth factor beta","volume":"65","author":"Christmann","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2019.02.010_bib0116","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/art.37742","article-title":"Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2019.02.010_bib0117","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1002\/art.39828","article-title":"Histone deacetylase 5 is overexpressed in scleroderma endothelial cells and impairs angiogenesis via repression of proangiogenic factors","volume":"68","author":"Tsou","year":"2016","journal-title":"Arthritis Rheumatol"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524419300428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524419300428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:38:11Z","timestamp":1761827891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524419300428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":117,"alternative-id":["S1931524419300428"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2019.02.010","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2019.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}